ReviewImmunological reviews2016
The comings and goings of MHC class I molecules herald a new dawn in cross-presentation.
Review in Immunological reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 64 citations in OpenAlex.
- Opportunities and challenges for cancer immunotherapy based on antigen cross-presentation.Annals of medicine · 2026Review
- Application of bacteriophages in the prevention and control of bacterial infectious diseases in animals.Frontiers in microbiology · 2026Review
- Molecular Mechanism for the Selective Presentation of Antigenic Peptides by Major Histocompatibility Complex Class I and Class II Molecules: A Hypothesis.Current issues in molecular biology · 2025Article
- Proteostasis of immune checkpoint receptors.The Biochemical journal · 2025Review
- ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4Journal of virology · 2025Article
- Regulatory gene network for coffee-like color morph of TYRP1 mutant of oujiang color common carp.BMC genomics · 2024Article
- Acute remote ischemic conditioning enhances (CD3+)- but not (FoxP3+)-T-cell invasion in the tumor center and increases IL 17 and TNF-alpha expression in a murine melanoma model.Frontiers in immunology · 2024Article
- pH-gated nanoparticles selectively regulate lysosomal function of tumour-associated macrophages for cancer immunotherapy.Nature communications · 2023Article
- Mining chicken ileal microbiota for immunomodulatory microorganisms.The ISME journal · 2023Article
- Different routes of MHC-I delivery to phagosomes and their consequences to CD8 T cell immunity.Seminars in immunology · 2023Review
- Signal regulatory protein beta 2 is a novel positive regulator of innate anticancer immunity.Frontiers in immunology · 2023Article
- A guide to antigen processing and presentation.Nature reviews. Immunology · 2022Review
- Nanoscale organization of the MHC I peptide-loading complex in human dendritic cells.Cellular and molecular life sciences : CMLS · 2022Article
- VAMP3 and VAMP8 Regulate the Development and Functionality of Parasitophorous Vacuoles Housing Leishmania amazonensis.Infection and immunity · 2022Article
- Advances in the Structural and Physiological Functions of SHARPIN.Frontiers in immunology · 2022Review
- Biological roles of the B cell receptor-associated protein 31: Functional Implication in Cancer.Molecular biology reports · 2021Review
- A Comprehensive Experimental Guide to Studying Cross-Presentation in Dendritic Cells In Vitro.Current protocols in immunology · 2020Article
- Focus on the morphogenesis, fate and the role in tumor progression of multivesicular bodies.Cell communication and signaling : CCS · 2020Review
- Polymorphisms of HLA-B: influences on assembly and immunity.Current opinion in immunology · 2020Review
- MHC Class I Stability is Modulated by Cell Surface Sialylation in Human Dendritic Cells.Pharmaceutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
MHC class I (MHC-I) molecules are the centerpieces of cross-presentation. They are loaded with peptides derived from exogenous sources and displayed on the plasma membrane to communicate with CD8 T cells, relaying a message of tolerance or attack. The study of cross-presentation has been focused on the relative contributions of the vacuolar versus cytosolic pathways of antigen processing and the location where MHC-I molecules are loaded. While vacuolar processing generates peptides loaded onto vacuolar MHC-I molecules, how and where exogenous peptides generated by the proteasome and transported by TAP meet MHC-I molecules for loading has been a matter of debate. The source and trafficking of MHC-I molecules in dendritic cells have largely been ignored under the expectation that these molecules came from the Endoplasmic reticulum (ER) or the plasma membrane. New studies reveal a concentrated pool of MHC-I molecules in the endocytic recycling compartment (ERC). These pools are rapidly mobilized to phagosomes carrying microbial antigens, and in a signal-dependent manner under the control of Toll-like receptors. The phagosome becomes a dynamic hub receiving traffic from multiple sources, the ER-Golgi intermediate compartment for delivering the peptide-loading machinery and the ERC for deploying MHC-I molecules that alert CD8 T cells of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.